腹腔镜技术治疗直肠癌安全性和有效性的应用研究

注册号:

Registration number:

ChiCTR-IOR-16009922 

最近更新日期:

Date of Last Refreshed on:

2016-11-19 20:47:42 

注册时间:

Date of Registration:

2016-11-19 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

腹腔镜技术治疗直肠癌安全性和有效性的应用研究

Public title:

Application of laparoscopy in the treatment of rectal cancer: safety and efficacy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

腹腔镜技术治疗直肠癌安全性和有效性的应用研究

Scientific title:

The safety and efficacy of laparoscopy in the treatment of rectal cancer

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

姜争 

研究负责人:

王锡山 

Applicant:

Zheng Jiang 

Study leader:

Xishan Wang 

申请注册联系人电话:

Applicant telephone:

+86 010 87788026

研究负责人电话:

Study leader's
telephone:

+86 010 87788026

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

zone-j@hotmail.com

研究负责人电子邮件:

Study leader's E-mail:

wxshan1208@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市朝阳区潘家园南里17号科研楼1103室

研究负责人通讯地址:

北京市朝阳区潘家园南里17号科研楼1103室

Applicant address:

17 Panjiayuan Street South, Chaoyang District, Beijing

Study leader's address:

17 Panjiayuan Street South, Chaoyang District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中国医学科学院肿瘤医院

Applicant's institution:

Cancer Hospital Chinese Academy of Medical Sciences

研究负责人所在单位:

中国医学科学院肿瘤医院

Affiliation of the Leader:

Cancer Hospital Chinese Academy of Medical Sciences

是否获伦理委员会批准:

Approved by ethic committee:

No

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中国医学科学院肿瘤医院

Primary sponsor:

Cancer Hospital Chinese Academy of Medical Sciences

研究实施负责(组长)单位地址:

北京市朝阳区潘家园南里17号

Primary sponsor's address:

17 Panjiayuan Street South, Chaoyang District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国医学科学院肿瘤医院

具体地址:

北京市朝阳区潘家园南里17号

Institution
hospital:

Cancer Hospital Chinese Academy of Medical Sciences

Address:

17 Panjiayuan Street South, Chaoyang District, Beijing

经费或物资来源:

北京市科委科技计划课题

Source(s) of funding:

Science and Technology Program of Beijing Municipal Science & Technology Commission

研究疾病:

直肠癌  

Target disease:

Rectal cancer

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本课题为多中心临床试验研究,采用非劣性、开放标签、随机对照的研究方法比较直肠癌开放性手术和腹腔镜手术的近期和远期疗效差异,并且评价不同腹腔镜手术术式的治疗效果。此外本课题以评分量表的形式对直肠癌术后功能性指标进行系统量化,并从免疫功能及应激反应等方面对两组疗效进行综合评估。  

Objectives of Study:

The objective of this study was to compare the short-term and long-term outcomes of open and laparoscopic surgery with noninferiority, open-label, and randomized controlled trials, and to evaluate the efficacy of different laparoscopic procedures. In addition to the scale of the subject in the form of functional indicators of rectal cancer after the system quantification, and from the immune function and stress response to the two groups to conduct a comprehensive assessment of efficacy.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

①ASA分级>III级;
②存在气腹禁忌证(如严重心肺功能不全者);
③5年内有盆腔恶性肿瘤病史者;
④急性肠梗阻的患者;
⑤满足经肛门局切标准的T1期直肠癌患者;
⑥既往多次行剖腹手术或腹腔广泛粘连者;
⑦家族性腺瘤性息肉病,林奇综合征相关性直肠癌以及炎症性肠病活动期的患者

Exclusion criteria:

1. ASA classification> Grade III;
2. Pneumoperitoneum contraindications (such as severe cardiopulmonary dysfunction);
3. The history of pelvic malignancy within 5 years ;
4. Acute intestinal obstruction;
5. meet the criteria of transanal excision of T1 rectal cancer patients;
6. underwent multiple laparotomy or abdominal adhesions widely;
7. familial adenomatous polyposis, Lynch syndrome-related rectal cancer and inflammatory bowel disease in patients with active period.

研究实施时间:

Study execute time:

From 2017-01-01 00:00:00 To 2020-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2017-01-01 00:00:00 To 2018-12-31 00:00:00

干预措施:

Interventions:

组别:

开腹组

样本量:

1000

Group:

Open group

Sample size:

干预措施:

开腹手术

干预措施代码:

Intervention:

open surgery

Intervention code:

组别:

腹腔镜组

样本量:

1000

Group:

laparoscopy group

Sample size:

干预措施:

腹腔镜手术

干预措施代码:

Intervention:

laparoscopic surgery

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

中国医学科学院肿瘤医院 

单位级别:

三甲医院 

Institution
hospital:

Cancer Hospital Chinese Academy of Medical Sciences

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

中国人民解放军总医院 

单位级别:

三甲医院 

Institution
hospital:

The General Hospital of the People's Liberation Army

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

北京大学肿瘤医院 

单位级别:

三甲医院 

Institution
hospital:

Beijing Cancer Hospital

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

北京大学人民医院 

单位级别:

三甲医院 

Institution
hospital:

Peking University People's Hospital

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京友谊医院 

单位级别:

三甲医院 

Institution
hospital:

Beijing Friendship Hospital, Capital Medical University

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

北京协和医院 

单位级别:

三甲医院 

Institution
hospital:

Peking Union Medical College Hospital

Level of the institution:

Tertiary A hospital

测量指标:

Outcomes:

指标中文名:

平均手术时间

指标类型:

主要指标

Outcome:

Mean operating time

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后疼痛评分

指标类型:

主要指标

Outcome:

Pain score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

并发症

指标类型:

主要指标

Outcome:

Complications

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后死亡率

指标类型:

主要指标

Outcome:

Postoperative mortality

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

总生存期

指标类型:

主要指标

Outcome:

overall survival time

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

无疾病生存期

指标类型:

主要指标

Outcome:

disease-free survival

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

我们将提前递送给第三方所有受试者的临床资料以及所有患者的编号,随机化是通过一个计算机模型完成,并只有制造商知道随机化状态。所有参与者将会在每个月固定时间收到由第三方设计的

Randomization Procedure (please state who generates the random number sequence and by what method):

The study medication is delivered by the third party inspection institution packed, labeled and numbered.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2021年5月1日,发表文章

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

publish paper in May 1st, 2021

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

由医渡云开发数据平台

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

the special metadata developed by YIDUCLOUD company

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2016-11-19 20:47:42